Revance Therapeutics, Inc. IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Revance Therapeutics, Inc. | RVNC - NASDAQ |
$14.00-$16.00 |
$16.00 |
$21.00 | 6 million | 2/6/2014 |
Cowen & Co., Piper Jaffray |
Co-Manager(s): |
Health Care |
Filing(s): Filed 2013-12-31
|
For IPO Boutique's "scale of 1 to 5" BUY rating on Revance Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".
Revance Therapeutics, Inc. Quote & Chart - Click for current quote -
RVNC
About Revance Therapeutics, Inc. (adapted from Revance Therapeutics, Inc. prospectus):
They are a clinical stage specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications.
This description is adapted from Revance RVNC prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as Revance RVNC "RVNC" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2024 IPO Boutique. All Rights Reserved